Elevar Tag

Press Releases & News

FORT LEE, N.J., Nov. 3 – Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for cancer patients, today announced that lirafugratinib (Lyrfigtu™) has been added

Read more

Combination achieved mOS of 23.8 months in patients with unresectable or metastatic HCC FORT LEE, N.J., Oct. 14 – Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences

Read more

Submission initiates regulatory process in European Union following U.S. submission, expanding global market presence Lirafugratinib is a highly selective, irreversible FGFR2 inhibitor differentiated from existing pan-FGFR therapies FORT LEE, N.J., Sept. 15 – Elevar Therapeutics, Inc., a majority-owned subsidiary of

Read more

In post hoc analysis of CARES-310 trial, combination improved mPFS versus sorafenib across age subgroups Combination also improved mOS versus sorafenib in patients <50 years and ≥50 years Elevar is sponsoring Sept. 3 welcome reception at ILCA Annual Conference Brussels,

Read more

FDA sets PDUFA target action date of July 23, 2026 Fort Lee, N.J., Jan. 30 – Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients

Read more